PURPOSE: The purpose of this Finnish total cohort survey was to assess and compare the self-reported health-related quality of life (HRQL) in childhood cancer survivors to that of matched controls, to analyse demographic and disease-related factors explaining survivors' HRQL, and to compare the results of two different HRQL instruments, 16D/17D and PedsQL™. METHODS: Questionnaires were mailed to 384 childhood cancer survivors and their randomly selected gender-, age- and living place-matched controls. Eligible survivors (aged 11-18 years) had been treated for extracranial malignancies ≤16 years of age, had survived ≥4 years after the diagnosis, and were currently free of cancer. RESULTS: Of them, 203 (52.9%) survivors and 266 (30.4%) controls replied. Survivors reported higher HRQL than their controls. Diagnostic group, additional non-cancer diagnosis, need of remedial education, and self-rated unhappiness correlated significantly with HRQL. The survivors of Wilms tumor, or neuroblastoma, had lower HRQL scores than the reference group (leukemia). The studied variables explained only 28% of the variation in HRQL scores among survivors. Instrument correlations were moderate (R = 0.40-0.65). CONCLUSIONS: Our findings suggest that the diagnosis of Wilms tumor or neuroblastoma may carry substantial risks for lower HRQL. The available background variables, however, explained less than one-third of the variation in the HRQL scores. Thus, other factors than demographic or cancer-related seem to play a significant role as determinants of HRQL.
PURPOSE: The purpose of this Finnish total cohort survey was to assess and compare the self-reported health-related quality of life (HRQL) in childhood cancer survivors to that of matched controls, to analyse demographic and disease-related factors explaining survivors' HRQL, and to compare the results of two different HRQL instruments, 16D/17D and PedsQL™. METHODS: Questionnaires were mailed to 384 childhood cancer survivors and their randomly selected gender-, age- and living place-matched controls. Eligible survivors (aged 11-18 years) had been treated for extracranial malignancies ≤16 years of age, had survived ≥4 years after the diagnosis, and were currently free of cancer. RESULTS: Of them, 203 (52.9%) survivors and 266 (30.4%) controls replied. Survivors reported higher HRQL than their controls. Diagnostic group, additional non-cancer diagnosis, need of remedial education, and self-rated unhappiness correlated significantly with HRQL. The survivors of Wilms tumor, or neuroblastoma, had lower HRQL scores than the reference group (leukemia). The studied variables explained only 28% of the variation in HRQL scores among survivors. Instrument correlations were moderate (R = 0.40-0.65). CONCLUSIONS: Our findings suggest that the diagnosis of Wilms tumor or neuroblastoma may carry substantial risks for lower HRQL. The available background variables, however, explained less than one-third of the variation in the HRQL scores. Thus, other factors than demographic or cancer-related seem to play a significant role as determinants of HRQL.
Authors: Judith Grant; Amy Cranston; John Horsman; William Furlong; Neil Barr; Sheri Findlay; Ronald Barr Journal: J Adolesc Health Date: 2006-05 Impact factor: 5.012
Authors: Maud M Geenen; Mathilde C Cardous-Ubbink; Leontien C M Kremer; Cor van den Bos; Helena J H van der Pal; Richard C Heinen; Monique W M Jaspers; Caro C E Koning; Foppe Oldenburger; Nelia E Langeveld; Augustinus A M Hart; Piet J M Bakker; Huib N Caron; Flora E van Leeuwen Journal: JAMA Date: 2007-06-27 Impact factor: 56.272
Authors: Wendy Demark-Wahnefried; Cary Werner; Elizabeth C Clipp; Ann Bebe Guill; Melanie Bonner; Lee W Jones; Philip M Rosoff Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: P M Lähteenmäki; H A Salmi; T T Salmi; H Helenius; A Mäkipernaa; M Lanning; M Perkkiö; M A Siimes Journal: Cancer Date: 1999-02-01 Impact factor: 6.860
Authors: Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller Journal: Eur J Cancer Date: 2009-02-21 Impact factor: 9.162